A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers

Trial Profile

A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Pexiganan (Primary)
  • Indications Bacterial infections; Diabetic foot ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms OneStep-1
  • Sponsors Dipexium Pharmaceuticals
  • Most Recent Events

    • 25 Oct 2016 Primary endpoint has not been met. (Clinical Response), as reported by a Dipexium media release.
    • 25 Oct 2016 Results published in the Dipexium Media Release.
    • 20 Oct 2016 According to a Dipexium media release, data tables and listings from this and another phase III trial are currently being produced and evaluated by the Company's scientific advisors according to the pre-specified data review procedure.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top